U.S. markets closed

Genprex, Inc. (GNPX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1900-0.0400 (-0.95%)
At close: 4:00PM EDT

4.1000 -0.09 (-2.15%)
After hours: 7:57PM EDT

Genprex, Inc.

Health Discovery Building
1601 Trinity Street Building B, Dell Medical Center Suite 3.312.09
Austin, TX 78712-1885
United States
877 774 4679
http://www.genprex.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. John Rodney VarnerCo, Founder, Pres, CEO, Sec. & Chairman429.68kN/A1957
Mr. Ryan M. Confer M.S.Chief Financial Officer341.71kN/A1982
Mr. Michael T. RedmanExec. VP & COON/AN/A1955
Ms. Catherine M. VaczyExec. VP, Gen. Counsel & Chief Strategy OfficerN/AN/A1961
Ms. Kalyn DabbsSr. Mang. of Communications & MarketingN/AN/AN/A
Mr. Thomas C. Gallagher Esq.Sr. VP of Intellectual Property & LicensingN/AN/AN/A
Dr. William E. Gannon Jr.Member of Clinical Advisory Board & VP of Regulatory AffairsN/AN/AN/A
Dr. Jack A. Roth F.A.C.S., FACS, M.D.Chairman of Scientific & Medical Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.